Results · Apr-Jun 2026
Shukra Pharmaceuticals Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 336% to ₹23.5 crore from ₹5.4 crore in Apr-Jun 2025.
Operating profit grew 1508% to ₹21.2 crore, an operating margin of 90.2% (up 65.7 points from a year ago).
Net profit grew 1360% to ₹15 crore from ₹1 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +273%, net profit turns positive.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 23.5 | 5.4 | +336% |
| Operating profit (EBITDA) | 21.2 | 1.3 | +1508% |
| Operating margin | 90.2% | 24.5% | +65.7 pts |
| Net profit | 15.0 | 1.0 | +1360% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.